In today’s increasingly collaborative healthcare ecosystem, effective partnerships and meaningful program support are more than operational niceties—they’re strategic imperatives. Archo.io’s 2024–2025 industry review pulls back the curtain on which companies are leading the way, how stakeholders perceive their contributions, and where unmet needs present future growth opportunities.
Archo.io surveyed a wide range of healthcare stakeholders to identify the top companies they’ve partnered with over the past 12–18 months. The methodology focused on:
The results revealed both brand strength and depth of impact in areas such as disease education, advisory boards, and patient support.
Janssen dominated the rankings with exceptional scores in:
Pfizer/Seagen saw major strength in:
Sanofi/Genzyme rose sharply due to:
Archo.io identified several critical need-gap areas—categories with high stakeholder interest but low actual support from companies:
These present opportunities for companies to expand support and better align with expectations.
Integrated Oncology Networks are gaining prominence, as seen with Pfizer/Seagen’s surge.
As healthcare moves beyond transactional engagements, the new frontier is transformational partnerships—those that influence clinical outcomes, drive innovation, and elevate patient experiences. Companies that embrace these principles not only win recognition but shape the future of global health collaboration.
Archo.io’s review sets the bar for what excellence looks like. The question is: who’s ready to meet—and exceed—it?
